In 1949 Koets reported a variation in the urinary 1 7-ketosteroid excretion occurring during the menstrual cycle of women with benign hirsutism, the maximal excretion being at, or about, the presumed time of ovulation.
The clinical features of the abnormal group are summarized in Table I . In no case was there a family history of hirsutism. It seems worth pointing out that the onset of the hirsutism in four cases (Nos. 6, 7, 8, and 10) dated from the occurrence of severe emotional upset and personal unhappiness.
Methods
Urine specimens were collected in bottles containing 3 g. of a mixture of powdered thymol and salicylic acid (2 : 1 w/w) to prevent bacterial growth (Bisset, Brooksbank, and Haslewood, 1948) . Estimations were made within 24 hours of the completion of the collection of urine wherever possible, and never more than 48 hours after the collection was finished. Where any delay occurred, specimens were stored at 2-4o C. until they were processed.
Pregnanediol was estimated by the method of Sommerville, Gough, and Marrian (1948) . Extracts of the urine containing the neutral ketonic fraction were prepared by the method of Talbot, Butler, and MacLachlan (1940) , modified only as regards the preparation of the crude neutral fraction, which was carried out as follows: Urine, 250 ml., and sulphur-free toluene, 50 ml., were placed in a flask of 500 ml. capacity which was attached by a ground glass joint to a bulb reflux condenser. The urine was brought to the boil on an electric hot-plate and 25 ml. concentrated hydrochloric acid added down the condenser. Boiling was continued for exactly 10 minutes. The apparatus was then disconnected and the flask and contents cooled rapidly in running water.
The urine-toluene mixture was transferred to a separating funnel of 1,000 ml. capacity and shaken. Separation of the emulsion was aided by filtration through a Whatman No. 1 filter paper on a Buchner funnel using gentle suction. The urine which separated from the emulsion was added to the urine pool before each subsequent extraction. The urine was extracted twice more with 50 ml. toluene, separation of the emulsion being similarly effected.
The combined toluene extracts were washed three times with 50 ml. 10% (w/v) sodium hydroxide solution, and twice with 50 ml. distilled water.
The extract was then dried with anhydrous sodium sulphate and the toluene evaporated on a boiling water bath at a pressure of 30 mm. of mercury.
The colorimetric assay of the neutral ketonic fraction was performed by the method of Holtorff and Koch (1940) , except that the dilution of the final coloured solution was made with 70O/% ethanol instead of 95% as used by these authors.
Creatinine was estimated by the niethod of Folin (1905a) .
Results Table II shows the results of estimations of pregnanediol, 17-ketosteroids, and creatinine on the urines of four healthy subjects.
The creatinine excretion was estimated in order to exclude incompleteness of urine collections. Wang (1939) and Albanese and Wangerin (1944) have shown that the creatinine excretion in any individual is not so constant as was originally assumed by Folin (1905b) , and that fluctuations of the order of 10 to 25 % are the rule. (Figures   in parentheses in Tables II and III refer to the concentration of steroids in mg. per g. of creatinine). This method of correcting concentrations of steroids in 24-hour urine specimens to an approximately constant volume of urine for the individual was proposed by Jayle and Libert (1946) , and seems acceptable provided that there is no gross diuresis and the limitations of using the creatinine excretion as a yardstick are borne in mind. Reference to Table II shows that Subjects 1, 2, and 3 exhibited increased luteal activity towards the end of the cycle, as shown by the rise in pregnanediol excretion to more than 1.5 mg. a day. Venning and Browne (1937) and Cope (1940) showed that the excretion of pregnanediol in the luteal phase of the menstrual cycle varied from 1 to 8 mg. of the conjugated excretory product, pregnanediol glucuronide, daily; during the follicular phase only minimal quantities are usually excreted. Case 4 failed to show any real peak of pregnanediol excretion; it is possible that her peak excretion was missed through doing the estimations at weekly intervals, but experience of doing the estimations in this way suggests that this was unlikely, and that she did not, in fact, show any increase of luteal activity and therefore did not ovulate (Venning and Browne, 1937) .
The 17-ketosteroid excretion of all these subjects varied during the cycle by a maximum of 3.3 mg. (Subject 4), the greater fluctuation found in Subject 1 being almost certainly attributable to the fact that the first urine specimen was incomplete. There is a tendency in all subjects for the 17-ketosteroid excretion to increase towards the middle or end of the cycle. Table III shows the results of estimations of pregnanediol, 17-ketosteroids, and creatinine on the urines of ten women with hirsutism.
Case 9 did not show any luteal activity, as revealed by a rise in pregnanediol excretion during her cycle. She is therefore comparable with Subject 4 of the healthy series (Table II) .
Case 8, who had had amenorrhoea for 13 months before the experiment and during it, consistently excreted amounts of pregnanediol which might normally be expected during the luteal phase of the cycle. This finding was associated with a raised 17-ketosteroid excretion throughout. It is possible that the colour developed by pregnanediol in the estimations may have been enhanced by the presence of abnormal amounts of 17-ketosteroids, thus giving a falsely high result (Sommerville et al., 1948) . On the other hand, if the pregnanediol results are true ones, it supports the possibility that this is a case of suprarenal hyperplasia rather than benign hirsutism, since ovarian tumour was excluded at clinical examination. It is doubtful whether Case 3 can be regarded as having shown any luteal activity. The second urine collection from this patient was almost certainly incomplete, and there is reason to believe that the third specimen was collected over a period of more than 24 hours. The results of pregnanediol estimations imply that no definite peak of excretion occurred.
The remaining cases all excreted an increased amount of pregnanediol towards the end of their cycles, the quantity varying from 1.88 mg. by Case 10 to 6.65 mg. by Case 2. Case 2 is of additional interest, since the levels of pregnanediol excretion during the follicular phase were higher than is usual.
The 17-ketosteroid excretion of these cases, in which the results of the pregnanediol estimations indicate ovulation, show a marked cyclical fluctuation. This is most pronounced in Cases 2, 4, 5, and 6, and less so in Cases 1 and 10; There is little doubt that it would have been more significant in Case 7 if the third urine collection had not been incomplete. These findings contrast with those of the normal subjects and with those of Case 9. She did not apparently ovulate, and her 17-ketosteroid excretion decreased slightly throughout the month.
The peak of 17-ketosteroid excretion seems to coincide with that of pregnanediol, a fact emphasized by the results in Case 9, where no peak of pregnanediol excretion was detected, and no cyclical variation of 17-ketosteroid excretion occurred.
Discussion
These results confirm Koets's (1949) findings of a variation in 17-ketosteroid excretion occurring during the menstrual cycle of hirsute women who ovulate. However, instead of the peak 17-ketosteroid excretion occurring at the time of ovulation, as Koets asserted, the results presented here relate it closely to luteal activity and the excretion of pregnanediol. It is possible that this association may be quite fortuitous, the increased excretion of 17-ketosteroids being attributable directly to ovarian activity, since Parkes (1937) and Deanesly (1938) have produced some evidence for ovarian secretion of androgenic material, which as yet remains unidentified: or the suprarenal cortex may be stimulated to increased 17-ketosteroid production by some substance produced in the ovary or elsewhere at this time in the cycle. The latter possibility is being investigated and the results will be published later. It is enough to say that so far there is no indication of any increase of suprarenal activity with respect to the excretion of other steroids at the time when 17-ketosteroid excretion is maximal.
It may be that the substance participating in the Zimmerman reaction, and thus contributing to the colour formed by 17-ketosteroids in the urine extracts, is not itself a 17-ketosteroid but a 20-ketosteroid such as pregnanolone, which is known to be an intermediate metabolite of progesterone.
If the excretion of pregnanediol and of 17-ketosteroids in benign hirsutism is related, the possibility that this points to an abnormality of progesterone metabolism cannot be ignored. Marrian (1939) suggested a possible metabolic pathway for the conversion of progesterone to C19 17-ketosteroids, but it has not so far proved possible to establish by isolation studies that such a process occurs, in spite of the strong theoretical probability. It is conceivable that in the hirsute woman there is an exaggeration of normal progesterone metabolism along these lines. Preliminary observations on this aspect of the problem have been started in this Department, but it is too early to draw any definite conclusions yet.
Summary
Pregnanediol and 17-ketosteroid estimations were made at intervals during the menstrual cycles of four healthy women and ten women with hirsutism.
In contrast to the healthy group the women with hirsutism who ovulated showed a distinct cyclical fluctuation of 17-ketosteroid excretion, which was apparently related to the peak of pregnanediol excretion occurring during the luteal phase of the cycle. One hirsute woman, who did not show any peak of pregnanediol excretion, showed no increase of 17-ketosteroid excretion.
The results are discussed, and further steps in the work indicated. 
